ginsenoside rh2 has been researched along with levofloxacin in 1 studies
| Studies (ginsenoside rh2) | Trials (ginsenoside rh2) | Recent Studies (post-2010) (ginsenoside rh2) | Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) |
|---|---|---|---|---|---|
| 295 | 1 | 200 | 4,346 | 581 | 2,209 |
| Protein | Taxonomy | ginsenoside rh2 (IC50) | levofloxacin (IC50) |
|---|---|---|---|
| Replicase polyprotein 1ab | Betacoronavirus England 1 | 7.6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, XY; Hao, K; Liu, Y; Qian, F; Sun, Y; Wang, GJ; Wang, YY; Zha, WB; Zhang, JW; Zhou, F | 1 |
1 other study(ies) available for ginsenoside rh2 and levofloxacin
| Article | Year |
|---|---|
Ginsenoside 20(S)-Rh2 promotes cellular pharmacokinetics and intracellular antibacterial activity of levofloxacin against Staphylococcus aureus through drug efflux inhibition and subcellular stabilization.
Topics: Animals; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Drug Stability; Female; Ginsenosides; Humans; Intracellular Fluid; Levofloxacin; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Staphylococcus aureus; Subcellular Fractions; THP-1 Cells | 2021 |